INSYS Therapeutics (INSY) is in Overbought Territory: What's Next?
INSYS Therapeutics, Inc.INSY has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because INSY is now in overbought territory with an RSI value of 71.37.
What is RSI?
RSI stands for 'Relative Strength Index' and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.
Yet INSY's high RSI value isn't the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in INSYS Therapeutics' stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of INSY's prospects for the near term.
Over the past two months, investors have witnessed 2 earnings estimates revision lower compared to none higher for the current year. The consensus estimate for INSY has also been on a downward trend over the same time period too, as the estimate has fallen from $0.13/share two months ago to just $0.04/share today.
If this wasn't enough, INSYS Therapeutics also has a Zacks Rank #4 (Sell)which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.